Pharmaceuticals

PROCAPS GROUP S.A.

PROCAPS GROUP S.A. released FY2024 earnings on March 16 (EST), actual revenue USD 373.8 M (forecast USD 471.5 M), actual EPS USD -0.6811

Procaps Group to Hold Shareholders' Meeting to Discuss Name Change and Financial Statement Revision

PROCAPS GROUP S.A. released FY2023 earnings on September 3 (EST), actual revenue USD 423.75 M (forecast USD 425.1 M), actual EPS USD 0.3994

PROCAPS GROUP S.A. released FY2021 earnings on September 3 Pre-Market (EST), actual revenue USD 403.74 M (forecast USD 411 M), actual EPS USD -1.0901

PROCAPS GROUP S.A. released FY2022 earnings on September 3 Pre-Market (EST), actual revenue USD 403.2 M (forecast USD 415.9 M), actual EPS USD 0.3572

Procaps Group SA reports 5.1% net income growth in 2023 reaching $423.7 million

EpicQuest Edu

VisionSys AI

Fitness Champs

Firefly Neuroscience

Kodiak Sciences

Greenland Energy

NOODLES

Olaplex

OceanPal

MKD Tech

禮來

ROCHE HOLDINGS AG

羅氏(ADR)

諾華制藥

阿斯利康

諾和諾德公司

中外制藥(ADR)

UCB(ADR)

大塚制藥(ADR)

第一三共株式會社(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

PROCAPS GROUP S.A.(PROCF.US)

PROCAPS GROUP S.A. Stock Performance Chart